Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Event**: Key opinion leader-investor event focused on statin intolerance and cardiovascular health - **Date**: November 11, 2025 Key Points Financial Performance - **Q3 Total Revenue**: $87.3 million, representing a nearly 70% year-on-year growth [3] - **Q3 US Net Product Sales**: $40.7 million, indicating a 31% year-on-year growth [3] - **Retail Prescription Equivalents**: 9% increase quarter-over-quarter [4] Product Development and Market Position - **Nexletol and Nexlizet**: Outpacing the broader lipid-lowering market and exceeding growth of other non-statin therapies [4] - **Statin Intolerance**: Approximately 50% of patients starting statin therapy discontinue or have significant gaps in treatment within two years, highlighting a market opportunity for Nexletol and Nexlizet [5] - **Direct-to-Consumer Advertising**: Launched on platforms like Disney+ and Hulu, achieving over 6 million impressions since October [7] Clinical Insights - **Statin Intolerance Definition**: Up to 30% of US adults experience some degree of statin intolerance, which can lead to non-adherence and increased cardiovascular risk [10][12] - **Bempedoic Acid**: Developed to address statin intolerance, it is a pro-drug that targets the liver, avoiding muscle-related side effects associated with statins [15] - **Clinical Trials**: Bempedoic acid has shown significant LDL cholesterol reduction and hsCRP lowering, with the Clear Outcomes trial being the only outcomes study in statin-intolerant patients [19][22] Market Access and Awareness - **Medicare and Commercial Approval Rates**: 87% for Medicare and 86% for commercial plans, indicating improved access for patients [8] - **Patient Copays**: Average copays are $29 and $36 for a 30-day supply, reflecting growing payer confidence [8] - **Awareness Challenges**: There is a significant gap in awareness among healthcare professionals regarding non-statin therapies, which affects adoption rates [52][56] Physician Perspectives - **Patient Characteristics**: Females and older individuals are at higher risk for statin intolerance, and many patients are unwilling to start statin therapy due to perceived side effects [12][14] - **Combination Therapy**: There is a growing trend towards using combination therapies to achieve LDL targets, especially in high-risk patients [40][41] - **Imaging Tools**: Physicians are increasingly using imaging to educate patients about their cardiovascular risk and the importance of LDL-lowering therapies [48] Future Outlook - **Guideline Updates**: Recent ESC guidelines emphasize the importance of non-statin therapies, with bempedoic acid receiving high recommendations for statin-intolerant patients [22] - **Educational Commitment**: Esperion is dedicated to educating both healthcare providers and patients about statin intolerance and available alternatives [23] Additional Insights - **Patient Education**: There is a need for better education regarding the risks of high LDL cholesterol and the importance of treatment adherence [56] - **Market Potential**: The potential market for bempedoic acid is significant, especially among primary care populations and patients with diabetes [58] This summary encapsulates the key insights and data presented during the conference call, highlighting Esperion Therapeutics' performance, product positioning, and the broader implications for cardiovascular health management.